A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
Tanguy Y. Seiwert(Georgetown University), Ezra E.W. Cohen(Moores Cancer Center), M. Degardin(Centre Hospitalier Universitaire de Nantes), Jérôme Fayette(Université Claude Bernard Lyon 1), Alice Blackman(Boehringer Ingelheim (United States)), W. Zhang(Boehringer Ingelheim (China)), Didier Cupissol(Institut de Recherche en Cancérologie de Montpellier), E. Ehrnrooth(Boehringer Ingelheim (Germany)), Paul M. Clément(Universitair Ziekenhuis Leuven), J.M. del Campo(Vall d'Hebron Hospital Universitari), Ricardo Hitt(Hospital Universitario Severo Ochoa)
Cited by 182
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
|New England Journal of Medicine|2008|3.7k